Novel therapies and innovation for systemic sclerosis skin ulceration

Tracy M. Frech; Madeleine Frech; Inga Saknite; Katie A. O'Connell; Shramana Ghosh; Justin Baba; Eric R. Tkaczyk

doi:10.1016/j.berh.2022.101813

Novel therapies and innovation for systemic sclerosis skin ulceration

Tracy M. Frech
, Madeleine Frech
, Inga Saknite
, Katie A. O'Connell
, Shramana Ghosh
, Justin Baba
, Eric R. Tkaczyk

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.

Original language	English
Article number	101813
Journal	Best Practice and Research: Clinical Rheumatology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1016/j.berh.2022.101813
State	Published - Dec 2022
Externally published	Yes

Funding

The Collaborative National Quality and Efficacy Registry is supported by the Scleroderma Research Foundation . This work was supported by the Veterans' Health Administration (VHA) Merit: 5I01CX002111-03 ( TMF ), VHA Career Development Award (CDA): IK2CX001785 (ERT).

Keywords

Capillaroscopy
Skin ulcer
Systemic sclerosis
Vasculopathy

Access to Document

10.1016/j.berh.2022.101813

Cite this

@article{25760d6b42224d64a5ec329009e2968d,

title = "Novel therapies and innovation for systemic sclerosis skin ulceration",

abstract = "Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.",

keywords = "Capillaroscopy, Skin ulcer, Systemic sclerosis, Vasculopathy",

author = "Frech, \{Tracy M.\} and Madeleine Frech and Inga Saknite and O'Connell, \{Katie A.\} and Shramana Ghosh and Justin Baba and Tkaczyk, \{Eric R.\}",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = dec,

doi = "10.1016/j.berh.2022.101813",

language = "English",

volume = "36",

journal = "Best Practice and Research: Clinical Rheumatology",

issn = "1521-6942",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Novel therapies and innovation for systemic sclerosis skin ulceration

AU - Frech, Tracy M.

AU - Frech, Madeleine

AU - Saknite, Inga

AU - O'Connell, Katie A.

AU - Ghosh, Shramana

AU - Baba, Justin

AU - Tkaczyk, Eric R.

PY - 2022/12

Y1 - 2022/12

N2 - Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.

AB - Skin ulceration is an important cause of morbidity in systemic sclerosis and can occur at anytime during disease progression. Incident disease cohorts are important for understanding whether skin ulceration represents active vasculopathy versus resultant damage. Biomarkers for skin ulcer pathogenesis, both serum and imaging, are under investigation to elucidate the functional consequences of the structural abnormalities. Novel therapeutics for the treatment of vasculopathy benefit from reliable biomarkers able to predict the disease evolution remains an important unmet need. Nonetheless, a diagnostic approach that captures early skin ulceration and treatments that restore vascular and immune homeostasis is critical for effective systemic sclerosis (SSc) vasculopathy management.

KW - Capillaroscopy

KW - Skin ulcer

KW - Systemic sclerosis

KW - Vasculopathy

UR - https://www.scopus.com/pages/publications/85145747534

U2 - 10.1016/j.berh.2022.101813

DO - 10.1016/j.berh.2022.101813

M3 - Review article

C2 - 36609122

AN - SCOPUS:85145747534

SN - 1521-6942

VL - 36

JO - Best Practice and Research: Clinical Rheumatology

JF - Best Practice and Research: Clinical Rheumatology

IS - 4

M1 - 101813

ER -

Novel therapies and innovation for systemic sclerosis skin ulceration

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this